Premium
Recalcitrant trametinib‐induced paronychia treated successfully with topical timolol in a pediatric patient
Author(s) -
MartínezdeEspronceda Inigo,
BernabeuWittel José,
Azcona Maialen,
Monserrat MariaTeresa
Publication year - 2019
Publication title -
dermatologic therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.595
H-Index - 68
eISSN - 1529-8019
pISSN - 1396-0296
DOI - 10.1111/dth.13164
Subject(s) - paronychia , medicine , trametinib , timolol , dermatology , mek inhibitor , surgery , kinase , mapk/erk pathway , intraocular pressure , biology , microbiology and biotechnology
Paronychia has been described as a side effect in patients undergoing treatment with MEK (mitogen activated protein kinase enzyme) inhibitors. It is usually a recurrent condition that can have a significant impact in the quality of life. Topical beta blocker treatment has been described as an effective therapy in antineoplastic‐induced pyogenic granulomas and in antineoplastic‐induced paronychia. We describe the first case treated with topical timolol for a trametinib‐induced paronychia in a pediatric patient that allowed to continue the third line antineoplastic therapy for his glioma.